The Filing Desk

HUTCHMED (China)

HCM · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

HCM · Last close · November 19, 2026
$13.45

HUTCHMED (China)'s revenue fell 13.0% to $548 million in fiscal 2025. Its operating margin was −7.1%, down from −6.9% a year earlier. Free cash flow was −$79 million.

HutchMED (China) LIMITED Latest fiscal year ended December 31, 2025 20-F filed March 5, 2026 · 0001104659-26-023822 Updated
Revenue
$548M
13.0%
Operating margin
−7.1%
0.2 pts
Net income
$457M
1111.0%
Free cash flow
−$79M
 
Return on equity
45.7%
40.7 pts

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity.

About these figures. Share counts and per-share figures for earlier years are restated for a stock split (10-for-1), so every year is on today's share basis. HUTCHMED (China) is a foreign company: it files an annual report on Form 20-F, prepared under US accounting standards (US GAAP), instead of a 10-K, and no quarterly reports, so this page has fiscal years only. Its shares trade in the US as American depositary shares (ADSs), and one ADS can stand for several ordinary shares, so per-share figures are per ordinary share and the page has no market value, P/E or valuation model.

What HUTCHMED (China) does

HUTCHMED is a drug company that started in China in 2000. It discovers, develops and sells targeted medicines for cancer and for diseases of the immune system. Three of its own drugs are sold in China under the names Orpathys, Elunate and Sulanda. Outside China, its partner Takeda sells fruquintinib as Fruzaqla, which has been approved in 38 countries, including the United States, Europe and Japan. AstraZeneca is its partner for savolitinib, and it has 15 more drug candidates in clinical trials.

Its consolidated revenue was $548.5 million in 2025. It comes from its cancer and immunology business, through sales of its drugs and payments from partners, and from what it calls Other Ventures, which make, market and distribute prescription drugs in China and brought in $263.0 million. Its own sales team in China numbers about 780 people.

In April 2025 it sold most of its stake in Shanghai Hutchison Pharmaceuticals, a joint venture with Shanghai Pharmaceuticals, keeping 5%. At the end of 2025 it had 1,796 full-time employees.

Its biggest risks, as it describes them

  • Its drug candidates may fail in clinical trials or not win approval, after long and costly development.
  • Its reliance on partners such as AstraZeneca and Takeda to develop and sell its drugs outside China.
  • Losing government reimbursement in China, or price cuts through centralized buying, could hurt sales.
  • Changes in Chinese law and policy, limits on moving money out of China, and the need to keep many permits.
  • Its shares in the United States could be delisted if US regulators cannot inspect its auditor.
From HUTCHMED (China)'s annual report on Form 20-F, filed March 5, 2026, in our words; the 20-F has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2016 to 2025, earnings per share grew 43.6% a year and net income 50.3% a year, as new shares raised the share count by 46% and diluted each share's earnings.

Diluted earnings per share
US$ per ordinary share, fiscal years; loss years in red. One US-listed ADS can stand for several ordinary shares.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments1,0126318868361,367
Debt incl. finance leases—18110106118
Net debt (negative means net cash)—−613−776−730−1,249
Net debt to EBITDA——−29.2x——
Debt to equity—0.0x0.1x0.1x0.1x
Interest coverage−554.6x−625.3x24.2x−15.2x−13.7x
Current ratio3.9x2.4x2.7x2.8x5.0x
Quick ratio3.8x2.2x2.6x2.7x4.8x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score7 of 94 of 94 of 9
Rule of 40118.8%−27.6%−27.3%
Altman Z''2.892.806.45
Accruals ratio−10.3%2.9%34.5%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positivePassPassPass
Cash from operations is positivePassPassFail
Return on assets rosePassFailPass
Cash from operations exceeds net incomePassFailFail
Debt fell relative to assetsFailPassPass
Current ratio rosePassPassPass
Share count didn't riseFailFailFail
Gross margin rosePassFailFail
Revenue rose relative to assetsPassFailFail
F-score7 of 94 of 94 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put HUTCHMED (China) side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
HUTCHMED (China)FY25−13.0%−7.1%−14.4%——4
Mirum PharmaceuticalsFY2554.7%−4.2%10.5%−7.1%−34.9x5Compare
BridgeBio PharmaFY25126.3%−104.2%−89.0%——3Compare
InsmedFY2566.7%−205.6%−159.6%——5Compare
OPKO HealthFY25−14.9%−19.4%−31.4%−7.0%—4Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue216241214205228356426838630548
Revenue growth21.2%11.6%−11.2%−4.3%11.3%56.2%19.7%96.5%−24.8%−13.0%
Gross profit6771————115454281212
Research and development6776114138175299387302212148
Operating income−47−53−93−146−197−328−40818−44−39
Net income12−27−75−106−126−195−36110138457
Diluted EPS (US$)0.02−0.04−0.11−0.16−0.18−0.25−0.430.120.040.52
Diluted shares (millions)600617664666698793847869873873
Cash flow
Cash from operations−10−9−33−81−62−204−2692190−65
Capital expenditure456981637331814
Free cash flow−14−14−39−89−70−221−305187−17−79
Dividends paid0000000000
Share buybacks11601327489360
Acquisitions0008000000
Stock-based compensation——————————
Balance sheet at fiscal year end
Cash and short-term investments1043583012174351,0126318868361,367
Debt incl. finance leases4730272727—18110106118
Total assets3425985324657241,3731,0291,2801,2741,753
Total liabilities138113120152205333393536502502
Shareholders' equity1844623892884849876107307601,238
Margins and ratios
Gross margin31.0%29.6%————27.0%54.1%44.6%38.7%
Operating margin−21.6%−22.1%−43.3%−71.5%−86.3%−92.2%−95.6%2.2%−6.9%−7.1%
Net margin5.4%−11.1%−34.9%−51.8%−55.1%−54.7%−84.6%12.0%6.0%83.3%
Free cash flow margin−6.4%−5.8%−18.3%−43.7%−30.7%−62.0%−71.6%22.3%−2.8%−14.4%
Rule of 40 (growth + FCF margin)14.8%5.8%−29.6%−48.0%−19.4%−5.7%−51.9%118.8%−27.6%−27.3%
Return on capital−27.6%−27.9%−50.0%−89.0%−133.3%—————
Return on equity8.7%−8.3%−17.6%−31.3%−32.6%−26.5%−45.2%15.0%5.1%45.7%
Return on assets4.1%−5.7%−13.2%−21.3%−21.1%−18.6%−30.0%8.7%3.0%30.2%
Net debt to EBITDA———————−29.2x——
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: HUTCHMED (China)'s Form 20-F filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with HUTCHMED (China).